Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study
Overall, the results of the PURSUIT 2 study support golimumab treatment for children with moderately-to-severely active UC. ClinicalTrials.gov ID: NCT03596645.
Authors
- AM Griffiths
- Jeroen Verhoeven (ORCID: https://orcid.org/0000-0002-6641-7760)
- Lakshmi Padgett
- Gigi Veereman
- Dan Turner (ORCID: https://orcid.org/0009-0004-8338-558X)
- Yevgeny Zitser
- Katherine Berezny
- Ben Kang
- Jeffrey S Hyams
- Richard S Strauss
- Gary Mao
- Omoniyi J Adedokun
Institutions
- Johnson & Johnson (United States) (US)
- Kharkiv State University of Food Technology and Trade (UA)
- Hospital for Sick Children (CA)
- Kyungpook National University Hospital (KR)
- Shaare Zedek Medical Center (IL)
- Connecticut Children's Medical Center (US)
- Children's Memorial Health Institute (PL)
- Kharkiv State Veterinary Academy (UA)
- Kharkiv National University of Internal Affairs (UA)
- Universitair Ziekenhuis Brussel (BE)
- Johnson & Johnson (Brazil) (BR)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1093/ibd/izaf322
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00